Perioperative immunotherapy in soft tissue sarcomas

Mené sur 143 patients atteints d'un sarcome des tissus mous des extrémités de stade localisé (durée médiane de suivi : 43 mois), cet essai randomisé évalue l'efficacité, du point de vue de la survie sans maladie, et la sécurité d'un ajout de pembrolizumab à une radiothérapie pré-opératoire

Résumé en anglais

Reducing the risk of metastatic relapse in patients with resectable soft tissue sarcomas is crucial for improving outcomes, because metastasis is the primary cause of mortality in this population. Approximately 40% of patients with localised soft tissue sarcomas develop distant metastases, leading to poor long-term survival. Although chemotherapy has traditionally been used in this setting, its role remains contentious due to inconsistent benefits in overall survival.